Essential Pharma Acquires HALDOL Rights from Janssen Pharmaceutica NV

Essential Pharma Acquires Reminyl Oral Capsules from Janssen Pharmaceutica

April 18, 2024

Pharmaceuticals

Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide) oral capsules from Janssen Pharmaceutica NV (a Johnson & Johnson company). The deal transfers rights in the EEA, South Korea, Thailand and other current markets (excluding the UK & Ireland, Japan and Latin America), expanding Essential Pharma’s CNS portfolio and its presence in the Asia‑Pacific region.

Essential Pharma Acquires Yorkdale Pharma from Rosemont; Sells Oral Liquid Portfolio to Rosemont and Buys Two Product Rights from Novartis

December 21, 2021

Pharmaceuticals

Gyrus Capital‑backed Essential Pharma completed a refinancing and executed a series of portfolio transactions in December 2021. Essential Pharma acquired Yorkdale Pharma Limited from Rosemont Pharmaceuticals, divested its 14‑product oral liquid portfolio (Essential Pharma Liquids Limited) to Rosemont, and also acquired worldwide (ex‑US, ex‑India) rights to two products from Novartis to expand its global specialty pharmaceutical portfolio.

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion

December 29, 2025

Biotechnology

Johnson & Johnson completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash, adding Halda's RIPTAC platform and clinical-stage prostate cancer candidate HLD-0915 to its oncology portfolio. The deal brings several earlier-stage RIPTAC-based programs for other solid tumors and positions J&J to advance oral targeted therapies that may overcome treatment resistance.

Pharmanovia Acquires Global CNS Portfolio from Sanofi

September 18, 2023

Pharmaceuticals

Pharmanovia, a Triton Fund V portfolio company, has acquired an 11‑brand global central nervous system (CNS) portfolio from Sanofi, including Frisium (clobazam) and Gardenal (phenobarbital). The asset package, available in 60+ markets, expands Pharmanovia's neurology franchise and commercial footprint across markets such as Brazil, South Africa, France and Italy in a divestiture from Sanofi.

Viatris Acquires Aculys Pharma to Secure CNS Assets and Japan/APAC Rights

October 15, 2025

Pharmaceuticals

Viatris Inc. has acquired clinical-stage Aculys Pharma, Inc., obtaining exclusive development and commercialization rights in Japan for pitolisant and rights in Japan and select Asia‑Pacific markets for Spydia (diazepam) nasal spray. The deal includes an upfront payment to Aculys shareholders with additional milestone and royalty payments, and is intended to strengthen Viatris' presence and CNS capabilities in Japan.

Essential Pharma Acquires Renaissance Pharma Ltd

April 2, 2024

Pharmaceuticals

Essential Pharma has completed the acquisition of all issued share capital of Renaissance Pharma Ltd, gaining the clinical-stage immunotherapy Hu14.18K322A (Hu14.18) for treatment of high‑risk neuroblastoma. The deal adds a development‑stage rare disease oncology asset to Essential Pharma's portfolio; Renaissance's CEO Simon Ball and members of the Renaissance team will continue to work with Essential on further development in partnership with St. Jude Children's Research Hospital.